macrogol 3350 + potassium chloride + sodium chloride + sodium hydrogen carbonate + sodium sulfate, anhydrous: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
macrogol 3350 + potassium chloride + sodium chloride + sodium hydrogen carbonate + sodium sulfate, anhydrous: clinical details
Prescribing considerations
- Confirm the indication is procedural bowel cleansing rather than routine constipation treatment.
- Assess aspiration risk, swallowing ability, consciousness, reflux, seizure history, inflammatory bowel disease and cardiac or renal comorbidity.
- Review oral medicines whose efficacy depends on reliable gastrointestinal absorption.
- Consider the substantial sodium content in patients following a controlled-sodium diet and the potassium content in renal impairment or controlled-potassium diets.
- Aspartame is a phenylalanine source and is relevant in phenylketonuria.
Contraindications and cautions
- Hypersensitivity to an active substance or excipient
- Known or suspected gastrointestinal obstruction or perforation
- Ileus or gastric retention
- Toxic colitis or toxic megacolon
- Severe congestive cardiac failure classified as NYHA III or IV
Monitoring
- Consider baseline and post-treatment electrolytes and renal function in frail patients or those with clinically significant renal impairment or electrolyte risk.
- Consider ECG assessment where arrhythmia or relevant cardiac risk is present.
- Observe patients at risk of aspiration or regurgitation, particularly during nasogastric administration.
- Investigate neurological symptoms, sudden abdominal pain with rectal bleeding, or persistent forceful vomiting promptly.
Clinical pharmacology
Macrogol 3350 acts osmotically within the gastrointestinal tract and is virtually unabsorbed. Increased intestinal water and volume promote colonic motility and evacuation; most of the preparation is eliminated in faeces.
Formulation and product differences
- The selected formulation contains macrogol 3350, anhydrous sodium sulfate, sodium hydrogen carbonate, sodium chloride and potassium chloride.
- It is a vanilla-flavoured powder containing aspartame and is intended for high-volume procedural bowel cleansing.
- The current eMC listing for the selected Klean-Prep presentation is marked discontinued; availability should therefore be confirmed through local supply channels.
macrogol 3350 + potassium chloride + sodium chloride + sodium hydrogen carbonate + sodium sulfate, anhydrous interactions
Rapid bowel emptying can reduce absorption of other oral treatments, and the macrogol component can affect some swallowing thickeners.
Oral medicines generally
Medicines taken around bowel cleansing may pass through without adequate absorption; follow the procedure team's instructions about separating or temporarily managing them.
Medicines with a narrow therapeutic index or short half-life
Reduced absorption may have greater clinical consequences, so medication planning may be required before the procedure.
Oral contraceptive pills
Rapid intestinal transit may reduce absorption; ask the procedure team or pharmacist about contraceptive precautions.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.